Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chiu, Kevin J
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Recruiting	3	700	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	10/27	12/30
HuVeM, NCT06035653: A Human Versus Machine Comparison Study	Recruiting	N/A	40	Europe		East and North Hertfordshire NHS Trust	Head and Neck Cancer	11/23	11/23
NCT05859828: The GOAL27-6 Study	Recruiting	N/A	60	Europe		East and North Hertfordshire NHS Trust, Get A-Head Charitable Trust	Head and Neck Cancer	04/24	04/25